Branch Retinal Vein Occlusion Clinical Trial
Official title:
Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience
Retinal vein occlusion (RVO) is the second leading cause of retinal vascular disease in
patients older than 50 years.The prevalence varies from 0.7% to 1.6% in the literature.
Visual recovery depends on ischemic damage of the retina, the occurence of macular edema
(ME) and the development of neovascular glaucoma. The occurence of ME is the main reason for
visual loss and frustrates visual recovery among patients with both central or branch RVO.
Therapeutic options that have been used and discussed over the years are the treatment with
anticoagulants, fibrinolytics, corticosteroids, acetazolamide and isovolemic haemodilution.
Furthermore, surgical options like vitrectomy and radial optic neurotomy were used.
Panretinal photocoagulation and grid pattern photocoagulation had established as additional
tool to induce chorioretinal anastomosis. Nevertheless, the effectiveness and the evidence
of these different treatment options could not be verified and remains mostly unknown.
Nowadays, intravitreal anti-VEGF application had become the treatment of choice for ME
secondary to RVO. Multi-center studies have already shown the effectiveness of anti-VEGF
treatment to reduce intraretinal fluid and retinal hemorrhages (BRAVO, CRUISE).
Unfortunately, often high numbers of re-treatments become necessary over the years. In our
knowledge, there are no reports showing more than 3 years treatment effects of
antiangiogenic drugs in patients with BRVO. However, the results of treatment effect longer
than 3 years are important, as the mean age < 70 years with an onset of BRVO has been
estimated in about 60% of all cases. In addition, most patients with regard to the
application of anti-VEGF treatment in real clinical setting, there is only rare experience
concerning need of optimum time duration for follow-up at the departments. Hence, the
present study aimed to evaluate the long-term clinical outcomes, safety and therapeutic
benefit of a flexible dosing regimen of intravitreal anti-VEGF therapy in patients with ME
secondary to BRVO.
This cross-sectional study evaluates a series of patients with ME due to RVO who were available for at least 4 years' follow-up examination. The patients received either intravitreal ranibizumab (IVR) or bevacizumab (IVB) in a flexible dosing regimen ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Active, not recruiting |
NCT04120311 -
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Not yet recruiting |
NCT04601688 -
Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
Completed |
NCT01968239 -
Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT
|
Phase 2 | |
Completed |
NCT00612261 -
Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion
|
N/A | |
Not yet recruiting |
NCT03637283 -
Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
|
N/A | |
Completed |
NCT01976338 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Completed |
NCT01247220 -
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
|
Phase 2 | |
Terminated |
NCT00642226 -
Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Terminated |
NCT05127525 -
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
|
Phase 3 | |
Completed |
NCT01599650 -
Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
|
Phase 3 | |
Active, not recruiting |
NCT04120636 -
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Recruiting |
NCT01975103 -
Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A | |
Completed |
NCT04740905 -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT02527733 -
Retinal Sensitivity in BRVO After Anti-VEGF Therapy
|
Phase 4 | |
Completed |
NCT01396057 -
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Terminated |
NCT03802630 -
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
|
Phase 3 | |
Completed |
NCT02478515 -
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
|
Phase 4 |